Precision AI Solutions

What Precision AI Solutions does

Precision AI Solutions is a private, early-stage precision oncology company founded in 2022 and headquartered in San Mateo, California. Its sole commercial offering, Oncology CoPilot, is an AI-powered drug-cancer biological network analysis platform that ingests Next-Generation RNA Sequencing (RNAseq) data and cross-references each patient against a proprietary reference database of 12,000+ treatment histories, 20,000 coding genes, and 150+ therapies to generate personalized therapy recommendations ranked by predicted drug response across more than 240 drug options. The platform is positioned as an investigational clinical decision-support tool for oncologists, diagnostic laboratories, and research organizations, with current emphasis on pancreatic cancer, triple-negative breast cancer (TNBC), and rare cancers. Validation is being pursued through retrospective and prospective studies with Moffitt Cancer Center, the US National Cancer Institute, and the Pancreatic Cancer Action Network, and a partnership with Cellentia reduces RNAseq turnaround time from weeks to days.

The company operates an enterprise, direct-sales go-to-market with no publicly disclosed pricing; revenue is generated (in concept) via subscription or service-based access to the Oncology CoPilot platform, though no commercial revenue is currently reported and the product is labeled investigational-only and not FDA-approved. The company was co-founded by CEO Edwin Alphonso and CSO Sophia Ren, with additional C-suite leadership in product (Zheng Xu) and software engineering (Seth Leffel). As of early 2025, Precision AI Solutions is actively raising capital to build captive NGS lab capacity, complete product launch, and scale operations, indicating a pre-commercial, funding-dependent stage.

The technology stack centers on non-generative AI models trained on real-world clinical data rather than synthetic generation, claimed to achieve >70% accuracy in retrospective drug-efficacy prediction, with patent-pending AI interpretation technology and a filed provisional IP covering the NGS/AI integration. Customer-facing motion is consultation- and email-driven, targeting hospital tumor boards, diagnostic labs, and academic research programs; the company also engages in patient advocacy (PanCAN PurpleStride, Rarevillage) for top-of-funnel awareness.

Name

Precision AI Solutions

Legal name

Precision AI Solutions

Website

https://precision-ai.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Precision AI Solutions is a pre-revenue precision oncology company that offers Oncology CoPilot, an AI-driven platform analyzing RNA sequencing data to generate personalized cancer therapy recommendations for oncologists, diagnostic labs, and research organizations, with current focus on pancreatic, TNBC, and rare cancers.

Ownership category

akta.pro rank

Product category

Precision Oncology Software

NAICS

Software Publishers (513210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Prepackaged Software (7372), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

akta.pro secondary industries

Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Cancer genomics analysis
• AI treatment matching
• RNA sequencing analysis
• Precision oncology software
• Clinical decision support

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. AI Analysis Platform Subscription: The platform is positioned as a clinical decision support tool for oncologists and healthcare providers, likely involving subscription or service-based pricing for access to the Oncology CoPilot analysis platform and treatment recommendations.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Precision AI Solutions provides an AI-powered precision oncology platform, Oncology CoPilot, that analyzes high-throughput RNA gene expression profiling data from patient tumors to generate personalized cancer therapy recommendations ranked by predicted drug response. It combines NextGen RNA sequencing, AI-guided treatment matching, and functional drug testing into a unified clinical decision-support workflow across all cancer types.

Product overview

Precision AI Solutions offers a single unified product: the Oncology CoPilot Platform. This AI-powered platform analyzes gene expression profiling data from patient tumors to evaluate molecular characteristics, microenvironment, and immune responses, generating personalized therapy recommendations ranked by predicted drug efficacy. The platform covers all cancer types with access to over 240 drug options and leverages a proprietary database of 12,000+ patient treatment histories and 20,000 coding genes.

Differentiator

Problem solved

Functional benefit

Brands

• Oncology CoPilot: AI-powered drug-cancer biological network analysis software platform that analyzes gene expression profiling data to generate personalized therapy options ranked by probability of drug response.

Products and services

• Oncology CoPilot AI-powered drug-cancer biological network analysis software platform for oncologists, diagnostic laboratories, and research organizations. It analyzes high-throughput gene expression (RNA) profiling data to evaluate tumor biology including molecular subtyping, microenvironment, and immune response, then generates personalized therapy options ranked by probability of drug response across all cancer types with access to over 240 drug options. Currently a patent-pending investigational tool, not FDA approved.

Quantifiable outcome

• 73% accuracy rate in predicting patient response to standard-of-care chemotherapy regimens in retrospective cohort analyses
• +4 more outcomes

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• CellentiacoreTechnology or Integration · 1 January 2022Precision AI Solutions has partnered with Cellentia to expedite tumor analysis and reduce RNAseq processing time. The partnership enables turning the time between biopsy and test results from weeks into days. Cellentia's CEO Shian-Jiun (SJ) Shih serves on the Precision AI Solutions board of advisors, indicating a close strategic relationship. The partnership includes Lab-in-the-Loop testing of patient-derived organoids and circulating tumor cells to validate AI-driven insights.
• Moffitt Cancer CentercoreStrategic or Co-development PartnerLaunching clinical collaboration with Moffitt Cancer Center supporting validation in pancreatic cancer programs. Retrospective and prospective validation studies are being conducted in collaboration with leading academic institutions. Sophia Ren, the Chief Science Officer, previously conducted postdoctoral research at Moffitt Cancer Center.
• US National Cancer InstitutecoreStrategic or Co-development PartnerThe company has formed key partnerships with top tier cancer research institutions including the US National Cancer Institute for advancing precision oncology research and validation studies.
• Pancreatic Cancer Action Network (PanCAN)flagshipStrategic or Co-development PartnerAligned with Pancreatic Cancer Action Network initiatives including Know Your Tumor® and Precision Promise℠ to expand retrospective validation. The company participated in PanCAN PurpleStride 2026 event in San Francisco to raise awareness and support for pancreatic cancer research.
• RarevillageminorOthersPrecision AI Solutions has partnered with Rarevillage to support a young patient named Mo with an ultra-rare low-grade tumor that progressed to EGFR-driven sarcoma. The company analyzed Mo's clinical data through their platform to generate insights and potential treatment options shared with his care team. This partnership serves community outreach and awareness purposes.
• Academic InstitutionscoreStrategic or Co-development PartnerRetrospective and prospective validation studies in collaboration with leading academic institutions. Multiple cancer centers and institutions are involved across the country for scaling validation and democratizing access to precision medicine.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• SOPHiA Genetics: SOPHiA Genetics provides AI-driven analytics for genomic and transcriptomic data used by hospitals and labs for clinical interpretation. Comparable in delivering bioinformatics-driven interpretation of sequencing data to support clinicians, including in oncology.
• Caris Life Sciences: Caris offers molecular profiling plus AI-driven analysis (MI Profile, MI Cancer Seek) for therapy selection across solid tumors. Comparable in combining transcriptomic/multi-modal profiling with treatment recommendations for oncologists.
• Tempus AI: Tempus is the most direct competitor — an AI-powered precision medicine platform for oncology that ingests molecular and clinical data to support treatment selection, with a similar go-to-market targeting oncologists and tumor boards across cancer types.
• Personalis: Personalis provides whole-transcriptome sequencing (ImmunoID, NeXT Personal) to characterize tumors and inform immunotherapy and treatment selection. Highly comparable because it also centers RNA-based biology and AI interpretation for oncology decision support.

Broad incumbents

• Foundation Medicine: Foundation Medicine (a Roche subsidiary) is the dominant established oncology genomic profiling provider used by oncologists for therapy matching. Comparable because its comprehensive genomic profiling feeds into the same treatment-decision workflow that Oncology CoPilot addresses.
• Guardant Health: Guardant Health is a liquid-biopsy and genomic profiling incumbent serving oncologists for therapy selection and monitoring. Comparable as an established precision oncology decision-support data source, though focused on ctDNA rather than tissue transcriptomics.

Emerging players

• PierianDx: PierianDx provides a clinical genomics interpretation platform used by hospital labs to turn NGS results into actionable oncologist-ready reports. Comparable as a clinical decision support layer for tumor profiling, though without a proprietary therapy-matching AI.
• Owkin: Owkin applies AI to multimodal patient data (including genomics and pathology) for oncology research and therapeutic decision support. Comparable as a younger AI-oncology player with similar translational research partnerships and emerging clinical offerings.
• Molecular Health: Molecular Health offers an AI-enabled precision oncology decision support system (MH Guide) that maps tumor molecular profiles to therapeutic options. Comparable in providing ranked, evidence-based therapy recommendations to oncologists using AI over molecular data.
• GenomOncology: GenomOncology provides clinical genomics decision support software used by molecular pathology labs and oncologists to interpret NGS reports and match therapies. Comparable as a workflow-integrated oncology CDS vendor with a similar target customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/precision-ai-solutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precision AI Solutions